āagmanLoginNot investment advice. Data and computed figures, for information only.
Senores Pharmaceuticals Ltd
₹1,258.80
−₹22.70 (−1.77%)
NSE · 15 Oct 2026, close
Market Cap
₹6,079 Cr
CMP
₹1,258.80
52-wk High / Low
₹1,599 / 706
P/E
48.1
P/B
6.5
Book Value
₹203.0
Div Yield
0.00%
ROCE
15.0%
ROE
13.4%
Face Value
₹10
D/E
0.37
Price+71.9% over 1Y
āagman read
Computed by āagmanPiotroski F-Score
6
/ 9
6 of 9 F-score tests passed
Graham Number
₹338
√(22.5 × EPS × book value per share)
ROIC
8.2%
vs 11.2% sector median
Cash flow to profit
0.51
CFO / PAT
Above 1.0 = operating cash flow exceeded reported profit
Margin change
+536
bps OPM YoY
Operating margin vs the same quarter last year
Sustainable growth
13.4%
ROE × earnings retention ratio
ROE stability
5.5
pp σ
Standard deviation of ROE across periods. Lower = more stable
Holder deltas
QoQ
pp
Prom +0.00FII +2.98DII +0.15
Latest quarter vs the previous one
Cash-accrual divergence
4.2%
of assets
Low = accruals track cash flow
Strengths
+Price trades above its 200-day moving average (1.2x)
Watch-outs
−Latest ROCE of 15% trails the sector median of 17%
Peer comparison
| Name | P/E | Mar Cap ₹ Cr | ROCE % | ROE % |
|---|
Quarterly results
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79 | 102 | 80 | 101 | 103 | 114 | 138 | 162 | 171 | 175 | 180 |
| Expenses | 64 | 80 | 59 | 77 | 77 | 95 | 104 | 112 | 121 | 128 | 126 |
| Operating Profit | 15 | 22 | 21 | 23 | 26 | 19 | 34 | 50 | 50 | 47 | 54 |
| OPM % | 19.0% | 21.6% | 26.3% | 22.8% | 25.2% | 16.7% | 24.6% | 30.9% | 29.2% | 26.9% | 30.0% |
| Other Income | 1 | 2 | 0 | 2 | 5 | 12 | 3 | 5 | 7 | 18 | 3 |
| Interest | 2 | 3 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 8 | 7 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 6 | 8 | 8 | 9 | 10 |
| Profit before tax | 10 | 18 | 13 | 16 | 20 | 21 | 26 | 41 | 45 | 47 | 39 |
| Net Profit | 7 | 14 | 11 | 13 | 16 | 18 | 21 | 30 | 34 | 37 | 30 |
| EPS (₹) | 2.37 | 5.23 | 3.23 | 3.86 | 3.73 | 3.87 | 4.28 | 7.03 | 6.87 | 6.86 | 6.67 |
Profit & Loss
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales | 14 | 35 | 215 | 398 | 633 | 688 |
| Expenses | 12 | 23 | 173 | 309 | 464 | 487 |
| Operating Profit | 2 | 13 | 42 | 90 | 168 | 201 |
| OPM % | 14.3% | 37.1% | 19.5% | 22.6% | 26.5% | 29.2% |
| Other Income | 0 | 4 | 3 | 19 | 47 | 33 |
| Interest | 1 | 2 | 9 | 22 | 25 | 27 |
| Depreciation | 1 | 2 | 10 | 17 | 31 | 35 |
| Profit before tax | 1 | 12 | 25 | 71 | 159 | 172 |
| Net Profit | 1 | 8 | 33 | 58 | 122 | 131 |
| EPS (₹) | 1.01 | 8.59 | 10.31 | 12.72 | 25.05 | 27.43 |
Balance Sheet
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 9 | 10 | 31 | 46 | 46 | — |
| Reserves | 28 | 36 | 174 | 740 | 888 | — |
| Borrowings | 15 | 63 | 258 | 315 | 342 | — |
| Other Liabilities | 8 | 23 | 160 | 126 | 328 | — |
| Total Liabilities | 59 | 131 | 622 | 1,227 | 1,604 | — |
| Fixed Assets | 7 | 27 | 235 | 301 | 755 | — |
| CWIP | 8 | 34 | 97 | 172 | 17 | — |
| Investments | 15 | 16 | 0 | 0 | 4 | — |
| Other Assets | 29 | 53 | 289 | 754 | 827 | — |
| Total Assets | 59 | 131 | 622 | 1,227 | 1,604 | — |
Cash Flows
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity | −10 | −1 | −26 | −46 | 62 |
| Cash from Investing Activity | −24 | −48 | −54 | −429 | −121 |
| Cash from Financing Activity | 36 | 46 | 87 | 573 | −1 |
| Net Cash Flow | 2 | −3 | 8 | 98 | −60 |
Ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| ROCE % | — | 18.0 | 12.0 | 11.0 | 15.0 |
| ROE % | — | — | — | — | 13.4 |
| EPS (₹) | 1.01 | 8.59 | 10.31 | 12.72 | 25.05 |
| Book Value (₹) | — | — | — | — | 203.0 |
| Face Value (₹) | — | — | — | — | 10 |
| P/E | — | — | — | — | 48.1 |
| Div Yield % | — | — | — | — | 0.00 |
| NPM % | 7.1 | 20.5 | 15.1 | 13.9 | 17.9 |
| OPM % | 14.0 | 36.0 | 19.0 | 23.0 | 27.0 |
| D/E | 0.41 | 1.37 | 1.26 | 0.40 | 0.37 |
| P/B | — | — | — | — | 6.5 |
Growth
Compounded sales growth
3 years+162.0%
TTM+51.0%
Compounded profit growth
3 years+139.0%
TTM+87.0%
Stock price CAGR
Last year+80.0%
Return on equity
5 years14.0%
3 years14.0%
Last year13.0%
Documents
Corporate actions
Fundamentals from a third-party compiler of exchange filings; prices from the exchanges. Not investment advice.© 2026 āagman